Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Value Partners Group
Deal Size : $110.0 million
Deal Type : Series E Financing
Insilico Gains $110M Series E for AI-Driven Drug Discovery
Details : The financing aims to fund the clinical development of company's lead product INS018_055. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : INS018_055
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Value Partners Group
Deal Size : $110.0 million
Deal Type : Series E Financing